Generic Leqselvi Availability
Last updated on Apr 10, 2025.
Leqselvi is a brand name of deuruxolitinib, approved by the FDA in the following formulation(s):
LEQSELVI (deuruxolitinib phosphate - tablet;oral)
-
Manufacturer: SUN PHARM INDS INC
Approval date: July 25, 2024
Strength(s): EQ 8MG BASE [RLD]
Is there a generic version of Leqselvi available?
No. There is currently no therapeutically equivalent version of Leqselvi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Leqselvi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Treatment of hair loss disorders with deuterated JAK inhibitors
Patent 10,561,659
Issued: February 18, 2020
Inventor(s): Wagner Amanda T. & Cassella James V. & Graham Philip B. & Braman Virginia & Uttamsingh Vinita & Von Hehn Jana & Hamilton Colleen E.
Assignee(s): Concert Pharmaceuticals, Inc.Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I), or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.
Patent expiration dates:
- May 4, 2037✓
- May 4, 2037
-
Deuterated JAK inhibitor and uses thereof
Patent 11,919,907
Issued: March 5, 2024
Inventor(s): Silverman; I. Robert et al.
Assignee(s): Sun Pharmaceutical Industries, Inc. (Princeton, NJ)Disclosed is a JAK1 and/or JAK2 inhibitor of the following structural formula: ##STR00001##
or a pharmaceutically acceptable salt thereof. This invention also provides pharmaceutical compositions comprising a compound of Formula (I), optionally including additional therapeutic agents, and use in methods of treatment for hair loss disorders.Patent expiration dates:
- May 21, 2041✓✓
- May 21, 2041
-
Treatment of hair loss disorders with deuterated JAK inhibitors
Patent 12,076,323
Issued: September 3, 2024
Inventor(s): Wagner; Amanda T. et al.
Assignee(s): Sun Pharmaceuticals Industries, Inc. (Princeton, NJ)Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I): ##STR00001##
or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.Patent expiration dates:
- May 4, 2037✓
- May 4, 2037
-
Crystalline form of deuruxolitinib phosphate
Patent 12,247,034
Issued: March 11, 2025
Inventor(s): Wiedemann; Sean
Assignee(s): Sun Pharmaceutical Industries, Inc. (Princeton, NJ)The present disclosure is directed to polymorph Form 1 of 1H-pyrazole-1-propanenitrile, β-(cyclopentyl-2,2,3,3,4,4,5,5-d.sub.8)-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βR)-, phosphate (1:1) (deuruxolitinib phosphate). Also disclosed are methods of treatment using polymorph Form 1 of deuruxolitinib phosphate and methods of making polymorph Form 1 of deuruxolitinib phosphate.
Patent expiration dates:
- May 10, 2044✓✓
- May 10, 2044
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- July 25, 2029 - NEW CHEMICAL ENTITY
More about Leqselvi (deuruxolitinib)
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.